Medical Xpress

FDA approves Bimzelx for three new indications

The U.S. Food and Drug Administration has approved Bimzelx (bimekizumab-bkzx) for the treatment of adults with active psoriatic arthritis (PsA), adults with active nonradiographic axial ...
Nasdaq

UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

With three new indications, BIMZELX® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved in the U.S. for the treatment of four chronic immune-mediated inflammatory diseases ...
Nasdaq

BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

BIMZELX® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved for the treatment of adults with moderate-to-severe plaque psoriasis Approval is supported by three Phase 3 ...
Yahoo Finance

BIMZELX® (bimekizumab-bkzx) demonstrates superior efficacy over SKYRIZI® (risankizumab-rzaa) in psoriatic arthritis: BE BOLD Week 16 data

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
FiercePharma

UCB digs deeper into Bimzelx’s psoriatic arthritis win over Skyrizi

Two months after UCB revealed the success of Bimzelx in a head-to-head trial against AbbVie’s Skyrizi in patients with psoriatic arthritis (PsA), the Belgian drugmaker has unveiled the detailed ...
Seeking Alpha

AbbVie’s Skyrizi beaten by UCB’s Bimzelx in psoriatic arthritis

Belgian biopharma company UCB (UCBJY) announced on Wednesday that its arthritis therapy Bimzelx outperformed AbbVie’s (ABBV) immunology therapy Skyrizi in a head-to-head trial for psoriatic arthritis, ...
Newswire

BIMZELX® (bimekizumab injection) Receives Positive Reimbursement Recommendation from Canada's Drug Agency for Hidradenitis Suppurativa

Following an examination of clinical evidence and stakeholder input, Canada's Drug Agency (CDA-AMC) has recommended BIMZELX® (bimekizumab injection) for reimbursement with conditions for patients with ...
Yahoo Finance

UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Morningstar

BIMZELX® (bimekizumab-bkzx) Data in Hidradenitis Suppurativa Showed Improvements in Pain and Resolution of Draining Tunnels Sustained to Three Years

Reduction of draining tunnels sustained to three years: Of patients who had at least one draining tunnel at baseline, 48.2% had none at one year, and 62.9% at three years* – indicating sustained ...
Morningstar

BIMZELX® (bimekizumab-bkzx) demonstrates superior efficacy over SKYRIZI® (risankizumab-rzaa) in psoriatic arthritis: BE BOLD Week 16 data

BIMZELX is the first approved biologic therapy to demonstrate superior, head-to-head ACR50 joint outcomes in psoriatic arthritis: 49.1% of those receiving BIMZELX vs 38.4% receiving risankizumab ...
Medindia

BIMZELX® (bimekizumab-bkzx) demonstrates superior efficacy over SKYRIZI® (risankizumab-rzaa) in psoriatic arthritis: BE BOLD Week 16 data

ATLANTA, May 19, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced Week 16 data from the BE BOLD trial demonstrating superior ACR50 joint outcomes at Week 16 for BIMZELX® ...